Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Update

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 548,900 shares, a growth of 29.3% from the March 31st total of 424,500 shares. Based on an average daily volume of 145,500 shares, the days-to-cover ratio is presently 3.8 days. Approximately 1.0% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Guggenheim set a $2.50 price target on shares of Nautilus Biotechnology in a research report on Friday, February 28th.

Insider Activity at Nautilus Biotechnology

In related news, CEO Sujal M. Patel bought 53,300 shares of the stock in a transaction dated Wednesday, March 19th. The stock was acquired at an average price of $0.99 per share, for a total transaction of $52,767.00. Following the acquisition, the chief executive officer now owns 10,117,788 shares in the company, valued at approximately $10,016,610.12. This represents a 0.53 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 40.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Nautilus Biotechnology

Several institutional investors have recently added to or reduced their stakes in NAUT. Virtu Financial LLC acquired a new stake in Nautilus Biotechnology during the 4th quarter worth approximately $28,000. Cubist Systematic Strategies LLC purchased a new position in Nautilus Biotechnology in the 4th quarter valued at $34,000. Squarepoint Ops LLC purchased a new position in Nautilus Biotechnology in the 4th quarter valued at $44,000. SG Americas Securities LLC increased its stake in Nautilus Biotechnology by 56.3% in the 4th quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock valued at $46,000 after buying an additional 9,904 shares during the period. Finally, Palumbo Wealth Management LLC raised its position in Nautilus Biotechnology by 45.4% during the 4th quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock worth $48,000 after buying an additional 8,888 shares during the last quarter. Institutional investors and hedge funds own 50.71% of the company’s stock.

Nautilus Biotechnology Trading Down 1.1 %

Shares of NASDAQ NAUT opened at $0.68 on Friday. The stock has a market cap of $85.45 million, a P/E ratio of -1.21 and a beta of 1.39. Nautilus Biotechnology has a twelve month low of $0.66 and a twelve month high of $3.09. The stock has a 50 day moving average of $0.91 and a two-hundred day moving average of $1.67.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings results on Tuesday, April 29th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. As a group, research analysts predict that Nautilus Biotechnology will post -0.57 earnings per share for the current year.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.